David Bogoslaw
The Column Group is close to reaching its fundraising target of $600m apiece for its early-stage life science Fund V and later-stage Opportunity Fund III.
The fact three firms led by women raised multi-billion funds within a couple of months is worth celebrating, but female-led venture capital funds still account for a fraction of the industry.